Empower Cells, Change Lives
Recent News
Triumvira Submits Investigational New Drug (IND) Application to the FDA and Clinical Trial Application (CTA) to Health Canada to Evaluate TAC01-CD19, a T Cell Antigen Coupler Therapy, in Ph 1/2 TACTIC-19 Trial
AUSTIN, Texas & HAMILTON, Ontario & TORONTO - Triumvira Immunologics Inc. (Triumvira), a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, has simultaneously submitted an IND to the U.S. Food and...
read moreTriumvira Announces Addition of Veteran VP of Regulatory Affairs, Presentations at CellCAN and TRI-CON Conferences, and Attendance at Bio-Europe Partnering
AUSTIN, TX, and HAMILTON, ON, March 13, 2019 – Triumvira Immunologics, Inc., (Triumvira) a privately held biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, today announced the appointment of Cynthia Molina as Vice...
read moreQ&A with Dr. Paul Lammers, President and CEO of Triumvira Immunologics developing their T-Cell Antigen Coupler Technology to activate T-Cells in the treatment of Advanced Hematological Cancers and Solid Tumors
Dr. Paul Lammers President & Chief Executive Officer Triumvira Immunologics www.triumvira.com Interview conducted by: Lynn Fosse, Senior Editor, CEOCFO Magazine, Published - March 4, 2019 CEOCFO: Dr. Lammers, you have been president and CEO for a little over a year...
read more